Publications by authors named "Kluza J"

Peptidoglycans (PGNs) are structural polymers of the bacterial cell wall and a common microbial molecular pattern encountered by the immune system daily. Low levels of PGNs are constitutively present in the systemic circulation in humans and rise during inflammatory pathologies. Since all known PGN sensors are intracellular, PGN internalization is a prerequisite for the initiation of cellular immune responses.

View Article and Find Full Text PDF
Article Synopsis
  • Tumor dormancy is when cancer cells can hide and become resistant to treatments, making it hard to fully get rid of cancer.
  • The study looked at how these dormant cancer cells work using special models of leukemia and melanoma, using lots of different scientific techniques to understand their behavior and find new ways to treat them.
  • Researchers found unique gene mutations and changes in proteins in dormant cells, suggesting how they survive and resist therapies, which could help develop better treatments for patients.
View Article and Find Full Text PDF
Article Synopsis
  • Acute myeloid leukemias (AML) have a poor survival prognosis, and new treatments like quizartinib, a tyrosine kinase inhibitor (TKI), struggle to eliminate all leukemic cells.
  • Research indicates that leukemic cells can survive TKI treatment by relying on mitochondrial oxidative metabolism, particularly through glutamine oxidation.
  • Combining quizartinib with L-asparaginase shows potential in overcoming drug resistance and improving treatment effectiveness for patients with FLT3-mutated AML.
View Article and Find Full Text PDF

Background: The metabolism of cancer cells generally differs from that of normal cells. Indeed, most cancer cells have a high rate of glycolysis, even at normal oxygen concentrations. These metabolic properties can potentially be exploited for therapeutic intervention.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma (MM) is an incurable blood cancer linked to MYC gene alterations, which currently lack effective drug-targeting options.
  • Research identified glutaminase (GLS1) as a vital gene for the survival of MYC-overexpressing cells, while showing it is not a primary cancer driver.
  • The study indicates that combining GLS1 and NAMPT inhibitors could be a promising approach to treat MYC-driven multiple myeloma by targeting cellular energy and synthesis pathways.
View Article and Find Full Text PDF

Rac1 is a member of the Rho GTPase family which plays major roles in cell mobility, polarity and migration, as a fundamental regulator of actin cytoskeleton. Signal transduction by Rac1 occurs through interaction with multiple effector proteins, and its activity is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). The small protein is mainly anchored to the inner side of the plasma membrane but it can be found in endocellular compartments, notably endosomes and cell nuclei.

View Article and Find Full Text PDF

Nasopharyngeal carcinoma-derived small extracellular vesicles (NPCSEVs) have an immunosuppressive impact on the tumour microenvironment. In this study, we investigated their influence on the generation of tolerogenic dendritic cells and the potential involvement of the galectin-9 (Gal9) they carry in this process. We analysed the phenotype and immunosuppressive properties of NPCSEVs and explored the ability of DCs exposed to NPCSEVs (NPCSEV-DCs) to regulate T cell proliferation.

View Article and Find Full Text PDF

Triple negative breast cancer (TNBC) is an aggressive malignancy for which chemotherapy remains the standard treatment. However, between 3 and 5 years after chemotherapy, about half patients will relapse and it is essential to identify vulnerabilities of cancer cells surviving neoadujuvant therapy. In this study, we established persistent TNBC cell models after treating MDA-MB-231 and SUM159-PT TNBC cell lines with epirubicin and cyclophosphamide, and then with paclitaxel, for a total of 18 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are studying how a gene called NOD2 affects the way special immune cells called macrophages develop in people with Crohn's Disease.
  • They found that without NOD2, these immune cells don’t grow properly in the intestines, even if there are enough starting cells called monocytes.
  • This discovery might help find new treatments for Crohn's Disease by understanding how NOD2 works in the immune system.
View Article and Find Full Text PDF

Peptidoglycan (PGN), a polymeric glycan macromolecule, is a major constituent of the bacterial cell wall and a conserved pathogen-associated molecular pattern (PAMP) that triggers immune responses through cytosolic sensors. Immune cells encounter both PGN polymers and hydrolyzed muropeptides during infections, and primary human innate immune cells respond better to polymeric PGN than the minimal bioactive subunit muramyl dipeptide (MDP). While MDP is internalized through macropinocytosis and/or clathrin-mediated endocytosis, the internalization of particulate polymeric PGN is unresolved.

View Article and Find Full Text PDF

Cellular senescence is implicated in a great number of diseases including cancer. Although alterations in mitochondrial metabolism were reported as senescence drivers, the underlying mechanisms remain elusive. We report the mechanism altering mitochondrial function and OXPHOS in stress-induced senescent fibroblasts.

View Article and Find Full Text PDF
Article Synopsis
  • Therapy resistance is a big issue in treating acute myeloid leukemia (AML), and researchers have created a 'MitoScore' to identify patients with high oxidative phosphorylation in their cells.
  • AML cells that resist treatment with cytarabine (AraC) show reliance on certain mitochondrial proteins and respond well to a combination of venetoclax (VEN) and AraC, but not to VEN with azacytidine.
  • Further research found that resistant AML cells adapt by altering their mitochondrial functions, and targeting these adaptations could improve treatment outcomes, suggesting a potential strategy to alternate between VEN therapies based on MitoScore levels to boost effectiveness.
View Article and Find Full Text PDF

Mitochondrial dysfunctions are implicated in several pathologies, such as metabolic, cardiovascular, respiratory, and neurological diseases, as well as in cancer and aging. These metabolic alterations are usually assessed in human or murine samples by mitochondrial respiratory chain enzymatic assays, by measuring the oxygen consumption of intact mitochondria isolated from tissues, or from cells obtained after physical or enzymatic disruption of the tissues. However, these methodologies do not maintain tissue multicellular organization and cell-cell interactions, known to influence mitochondrial metabolism.

View Article and Find Full Text PDF

Resistant acute myeloid leukemia (AML) exhibits mitochondrial energy metabolism changes compared to newly diagnosed AML. This phenotype is often observed by evaluating the mitochondrial oxygen consumption of blasts, but most of the oximetry protocols were established from leukemia cell lines without validation on primary leukemia cells. Moreover, the cultures and storage conditions of blasts freshly extracted from patient blood or bone marrow cause stress, which must be evaluated before determining oxidative phosphorylation (OXPHOS).

View Article and Find Full Text PDF

Receptor-interacting protein kinase 3 (RIPK3) can induce necroptosis, apoptosis, or cell proliferation and is silenced in several hematological malignancies. We previously reported that RIPK3 activity independent of its kinase domain induces caspase-mediated p65/RelA cleavage, resulting in N-terminal 1-361 and C-terminal 362-549 fragments. We show here that a noncleavable p65/RelA D361E mutant expressed in DA1-3b leukemia cells decreases mouse survival times and that coexpression of p65/RelA fragments increases the tumorigenicity of B16F1 melanoma cells.

View Article and Find Full Text PDF

Objective: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable to fully eradicate dormant leukemic stem cells (LSC) indicate that new therapeutic strategies are needed to control LSC and to prevent relapse. In this study we investigated the metabolic pathways responsible for CML surviving to imatinib exposure and its potential therapeutic utility to improve the efficacy of TKI against stem-like CML cells.

View Article and Find Full Text PDF

SMIP004-7 is a small molecule inhibitor of mitochondrial respiration with selective in vivo anti-cancer activity through an as-yet unknown molecular target. We demonstrate here that SMIP004-7 targets drug-resistant cancer cells with stem-like features by inhibiting mitochondrial respiration complex I (NADH:ubiquinone oxidoreductase, complex I [CI]). Instead of affecting the quinone-binding site targeted by most CI inhibitors, SMIP004-7 and its cytochrome P450-dependent activated metabolite(s) have an uncompetitive mechanism of inhibition involving a distinct N-terminal region of catalytic subunit NDUFS2 that leads to rapid disassembly of CI.

View Article and Find Full Text PDF

Tobacco smoking is classified as a human carcinogen. A wide variety of new products, in particular electronic cigarettes (e-cigs), have recently appeared on the market as an alternative to smoking. Although the in vitro toxicity of e-cigs is relatively well known, there is currently a lack of data on their long-term health effects.

View Article and Find Full Text PDF

Metabolic reprogramming is crucial to respond to cancer cell requirements during tumor development. In the last decade, metabolic alterations have been shown to modulate cancer cells' sensitivity to chemotherapeutic agents including conventional and targeted therapies. Recently, it became apparent that changes in lipid metabolism represent important mediators of resistance to anticancer agents.

View Article and Find Full Text PDF

Mitochondrial metabolism must constantly adapt to stress conditions in order to maintain bioenergetic levels related to cellular functions. This absence of proper adaptation can be seen in a wide array of conditions, including cancer. Metabolic adaptation calls on mitochondrial function and draws on the mitochondrial reserve to meet increasing needs.

View Article and Find Full Text PDF

Nowadays ambient particulate matter (PM) levels still regularly exceed the guideline values established by World Health Organization in most urban areas. Numerous experimental studies have already demonstrated the airway toxicity of the fine fraction of PM (FP), mainly triggered by oxidative stress-induced airway inflammation. However, only few studies have actually paid close attention to the ultrafine fraction of PM (UFP), which is likely to be more easily internalized in cells and more biologically reactive.

View Article and Find Full Text PDF
Article Synopsis
  • The diagnosis of mitochondrial diseases is difficult due to their diverse symptoms and genetic variations, requiring clinical and genetic assessments alongside biochemical tests.
  • Researchers tested microscale XF technology to measure oxygen consumption in skin fibroblasts from pediatric patients with mitochondrial disorders, establishing a reliable protocol for key respiratory parameters.
  • They found a decrease in maximum respiration and spare respiratory capacity across all patients, suggesting microscale oxygraphy could be an effective initial screening method for OXPHOS deficiencies.
View Article and Find Full Text PDF

Although the brain accounts for only 2% of the total body mass, it consumes the most energy. Neuronal metabolism is tightly controlled, but it remains poorly understood how neurons meet their energy demands to sustain synaptic transmission. Here we provide evidence that AMP-activated protein kinase (AMPK) is pivotal to sustain neuronal energy levels upon synaptic activation by adapting the rate of glycolysis and mitochondrial respiration.

View Article and Find Full Text PDF

In order to clarify whether the mitochondrial dysfunction is closely related to the cell homeostasis maintenance after particulate matter (PM) exposure, oxidative, inflammatory, apoptotic and mitochondrial endpoints were carefully studied in human bronchial epithelial BEAS-2B, normal human bronchial epithelial (NHBE) and chronic obstructive pulmonary disease (COPD)-diseased human bronchial epithelial (DHBE) cells acutely or repeatedly exposed to air pollution-derived PM. Some modifications of the mitochondrial morphology were observed within all these cell models repeatedly exposed to the highest dose of PM. Dose- and exposure-dependent oxidative damages were reported in BEAS-2B, NHBE and particularly COPD-DHBE cells acutely or repeatedly exposed to PM.

View Article and Find Full Text PDF

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to BRAF inhibitors (BRAFi).

View Article and Find Full Text PDF